Analysis Tools
nervous system
homeostasis/metabolism
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease 3 | DOID:0110042 |
OMIM:607822 |
J:157228 | |
|
Allele Symbol Allele Name Allele ID |
Tg(PSEN1dE9)S9Dbo transgene insertion S9, David R Borchelt MGI:3618599 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease 3 | DOID:0110042 |
OMIM:607822 |
J:157228 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• amyloid beta levels and amyloid plaque burden are increased at 4.5 and 6 months of age, but not at 12 months of age, compared to transgenic mice wild-type for Sorl1 suggesting an acceleration in accumulation of amyloid beta
• some of the largest differences in amyloid measures are detected in the cerebellum
|
|
• amyloid beta levels and amyloid plaque burden are increased at 4.5 and 6 months of age, but not at 12 months of age, compared to transgenic mice wild-type for Sorl1 suggesting an acceleration in accumulation of amyloid beta
• some of the largest differences in amyloid measures are detected in the cerebellum
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease | DOID:10652 | J:142501 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice perform as well as control mice in platform and probe trials in Morris water maze tasks
|
|
• in open field test, mice are similar to Bace1tm1Pcw homozygotes, and spend more time in open area at center of field than at periphery
|
|
• swim speed is lower than other genotypes and nontransgenic mice in hidden and visible platform trials
|
| N |
• in 12- or 20-month old mice, no amyloid beta (Abeta) aggregation is detected in brains; no amyloid deposits are found
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are significantly impaired in Morris water maze tasks
|
|
• high level of amyloid beta aggregates are found in brain at 12 months of age
|
|
• in 12-month old brains, there is a 27% reduction in amyloid beta aggregates compared to transgenic mice that are wild-type for Bace1; there are no significant differences at 20 months
• in 12-month old brains, there is 37% reduction in percentage of brain volume occupied by amyloid beta deposits, but no difference at 20 months
|
|
• high level of amyloid beta aggregates are found in brain at 12 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice travel shorter distance in open-field and show less activity or excursions into central area; mice remain near periphery of apparatus rather than entering open center of field
|
|
• 16-18 month-old mice swim farther to find platform and spend less time in platform vicinity than controls
|
|
• one month following neuron injection with virus expressing short hairpin RNA to silence Bace1, there is a 38% reduction in amyloid beta burden in hippocampus compared to uninjected hippocampus
|
|
• mice display amyloid beta aggregates at 12 and 20 months
|
|
• one month following neuron injection with virus expressing short hairpin RNA to silence Bace1, there is a 38% reduction in amyloid beta burden in hippocampus compared to uninjected hippocampus
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease | DOID:10652 | J:123534 | ||
| Alzheimer's disease 3 | DOID:0110042 |
OMIM:607822 |
J:123534 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• develops diffuse, compact, birefringent congophilic plaques in cortex and hippocampus
(J:87691)
• ratio of amyloid beta peptide 40:42 is 0.75:1
(J:87691)
• 150% increase in amyloid beta peptide 42
(J:87691)
• at 7 months of age, mice exhibit amyloid plaques in the hippocampus and cortex
(J:104236)
|
|
• develops diffuse, compact, birefringent congophilic plaques in cortex and hippocampus
(J:87691)
• ratio of amyloid beta peptide 40:42 is 0.75:1
(J:87691)
• 150% increase in amyloid beta peptide 42
(J:87691)
• at 7 months of age, mice exhibit amyloid plaques in the hippocampus and cortex
(J:104236)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease | DOID:10652 | J:123534 | ||
| Alzheimer's disease 3 | DOID:0110042 |
OMIM:607822 |
J:123534 | |
| Alzheimer's disease 4 | DOID:0110040 |
OMIM:606889 |
J:123534 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• increase in microglial cell activity in retina is observed in 12-15 month old transgenics
• microglia processes in the retina are thicker and display a dendritic-like appearance as compared to control
• microglia density, but not cell body size, is increased in transgenics
|
|
• thioflavine-S positive plaques are observed in the retina beginning at 12 months of age
• plaques have radial branches with a central core
• plaque size ranges from 5-20 um, larger plaques are observed at 15-16 months
• plaques appear earlier in females than in males and increase in number over time
• 100% of females and 75% of males have plaques in retina by 15-16 months
|
|
• distribution of amacrine cell processes is disrupted as determined by syntaxin 1 staining
|
|
• thioflavine-S positive plaques are observed in the retina beginning at 12 months of age
• most plaques (34.7% and 41% respectively) are found in the inner and outer plexiform layers
• thickness of the retinal nuclear layers is similar to control, suggesting that there is no obvious neuronal cell loss
|
|
• distribution of amacrine cell processes is disrupted as determined by syntaxin 1 staining
|
|
• thioflavine-S positive plaques are first observed in females in the IPL at 12 months
• plaques are first observed in males at 13 months
• plaques are embedded within IPL cholinergic bands
|
|
• thioflavine-S positive plaques are first observed in females in the OPL at 12 months
• plaques are first observed in males at 13 months
|
|
• amplitudes of a and b waves are decreased in 12-16 month old mice when tested at lower light intensity, but not a higher intensity
• latency and implicit time as determined by ERG measurement are similar to control
|
|
• increase in microglial cell activity in retina is observed in 12-15 month old transgenics
• microglia processes in the retina are thicker and display a dendritic-like appearance as compared to control
• microglia density, but not cell body size, is increased in transgenics
|
|
• increase in microglial cell activity in retina is observed in 12-15 month old transgenics
• microglia processes in the retina are thicker and display a dendritic-like appearance as compared to control
• microglia density, but not cell body size, is increased in transgenics
|
|
• thioflavine-S positive plaques are observed in the retina beginning at 12 months of age
• plaques have radial branches with a central core
• plaque size ranges from 5-20 um, larger plaques are observed at 15-16 months
• plaques appear earlier in females than in males and increase in number over time
• 100% of females and 75% of males have plaques in retina by 15-16 months
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• immunoblotting of of cortical and hippocampal extracts from transgenic mice under conditions that distinguish mouse and human full-length PSEN1 and its endoproteolytic derivatives demonstrates failure of the transgenic protein to undergo endoproteolysis and, instead, accumulation of the full-length mutant human protein in the brain
• endoproteolytic cleavage products of endogenous mouse PSEN1 are 70-90% less abundant in brains of transgenic than of wild-type mice; however, failure of its cleavage does not result in accumulation of the full-length mouse protein
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Alzheimer's disease | DOID:10652 | J:104147 | ||
| Alzheimer's disease 3 | DOID:0110042 |
OMIM:607822 |
J:104147 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||